TromboseZorg Dichtbij

What TromboseZorg Dichtbij does

TromboseZorg Dichtbij (TZD) is a Dutch non-profit foundation (stichting) established in 2022 through the merger of the thrombotic services of Result Laboratorium and Canisius Wilhelmina Ziekenhuis (CWZ), headquartered in Druten, Gelderland, Netherlands. The organization provides anticoagulation management services for approximately 18,000 patients on Vitamin K antagonists (acenocoumarol and fenprocoumon), making it one of the larger thrombotic services in the Netherlands. Its core service is INR (International Normalized Ratio) monitoring and dose optimization, delivered through three modalities: standard monitoring via blood collection points operated by partner laboratories (CWZ, Result Laboratorium, Dicoon, Rijnstate); self-management via home POCT devices (CoaguChek XS or Micro INR Meter Link); and Near Patient Testing (NPT) at care institutions.

The underlying technology stack centers on the Tropaz web portal and mobile app — a digital platform that replaced the legacy Portavita system in April 2022 and enables patients to view dose cards, submit INR measurements, communicate with the thrombosis service, and manage appointments. Clinical dosing recommendations are generated through automated processing of structured INR data (Trodis/Tropaz), with mandatory physician review and approval. Operations are ISO 9001:2015 and FNT Veldnorm certified (KIWA Nederland, June 2022) and follow LSKA national care chain standards and LTA guidelines for VKA-DOAC transitions.

TZD generates revenue through three streams reimbursed under Dutch basic health insurance at NZa-set maximum tariffs: standard anticoagulation monitoring (annual billing via CWZ or Result Laboratory); self-management services (quarterly all-inclusive billing including equipment, strips, and supervision); and Near Patient Testing (special NZa rate, with care institutions receiving a portion). Patient acquisition is primarily referral-driven from cardiologists, internists, neurologists, and GPs, supplemented by hospital anticoagulation committee participation and self-enrollment via the website. Since March 2023, TZD has been a member of CAT (Centrum Antistolling Trombosezorg), a national partnership with six other thrombotic services providing shared 24/7 emergency consultation. Geographic expansion is ongoing, with the planned March 2026 transfer of Trombosedienst Gelderse Vallei (Dicoon) patients extending the service area into the Ede region.

Name

TromboseZorg Dichtbij

Legal name

Stichting TromboseZorg Dichtbij

Website

https://trombosezorgdichtbij.nl

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

TromboseZorg Dichtbij is a Dutch non-profit foundation that provides anticoagulation management — INR monitoring, dose optimization, and self-management — for approximately 18,000 patients on Vitamin K antagonists across multiple Dutch regions, using the Tropaz digital platform and partner-laboratory blood collection points.

Ownership category

akta.pro rank

Product category

Thrombosis Care Services (Anticoagulation Management)

NAICS

Medical Laboratories (621511)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer) (HLAHAOAC)

akta.pro secondary industries

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK), Cardiology Telemedicine Platforms (HLALAGAB)

Keywords

• Anticoagulation management
• Thrombosis care services
• INR monitoring
• Self-management dosing
• Vitamin K antagonist therapy

Headquarters

HQ city

Druten

HQ country

Netherlands

HQ region

Europe

Offices10 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Standard Anticoagulation Monitoring: Regular INR monitoring and dosing services for patients on Vitamin K antagonists (acenocoumarol and fenprocoumon). Blood samples collected at collection points by CWZ, Result Laboratory, and Dicoon. Invoicing handled through CWZ or Result Laboratory billing departments to health insurers. Treatment covered under basic health insurance.
2. Self-Management Services: Self-measurement program where patients measure INR at home using provided equipment (Coaguchek or Micro INR Meter). Quarterly invoicing through CWZ or Result Laboratory. Costs apply toward the (voluntary) deductible. Includes training, strips, chips, and supervision by medical staff.
3. Near Patient Testing (NPT): Care institutions perform INR testing on-site; TromboseZorg Dichtbij provides dosing. Special NZa-set rate applies, billed by CWZ or Result Laboratory to insurers. Care institution receives a portion of this tariff.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Core offering

TromboseZorg Dichtbij is a Dutch non-profit foundation providing anticoagulation treatment services for patients on Vitamin K antagonists (acenocoumarol and fenprocoumon). The core service is regular INR monitoring combined with personalized dose optimization, delivered through a network of partner laboratory blood collection points (CWZ, Result Laboratorium, Dicoon), supplemented by self-management programs at home using POCT devices and Near Patient Testing for residents of care institutions. The Tropaz digital portal and mobile app enable patients to view dose cards, submit INR measurements, and communicate with the thrombosis service.

Product overview

TromboseZorg Dichtbij is a thrombosis service offering anticoagulation treatment for patients in the Netherlands. The core service is the Anticoagulation Treatment program, supported by two main technology platforms: Tropaz (patient web portal and mobile app) for INR submission, dosing schedule access, and secure messaging; and Near Patiënt Testing (NPT) for institutional合作的 care. Patients can optionally participate in Zelfmeten (Self-Testing) programs using home INR devices. All services connect through the Tropaz digital platform.

Differentiator

Problem solved

Functional benefit

Brands

• Tropaz: Patient portal and web application for managing anticoagulation treatment, viewing dose schedules, and communicating with the thrombosis service.

Products and services

• Anticoagulation Treatment Core anticoagulation treatment service for patients on Vitamin K antagonists (acenocoumarol and fenprocoumon), including regular INR monitoring, personalized dose optimization, and patient management. Treatment is covered under Dutch basic health insurance, with billing handled through CWZ or Result Laboratory to insurers.
• Zelfmeten (Self-Testing / Self-Management) Self-management program where trained patients measure their own INR at home using CoaguChek or Micro INR Meter Link devices. Patients transmit results via the Tropaz portal and receive dosing guidance from TZD medical staff. Includes training, strips, chips, equipment, and supervision. Billed quarterly via CWZ or Result Laboratory.
• Near Patient Testing (NPT) Collaborative care model for care institutions (nursing homes and care cooperatives) where trained nursing staff perform INR measurements on-site using POCT meters. TZD provides dosing, supervision, and same-day dose advice via the Tropaz portal. A special NZa-set rate applies.
• Tropaz Patient Portal and Mobile App Secure web portal and mobile app (available via Google Play Store and Apple App Store) that allows patients to view dosing schedules, submit INR measurements, communicate with the thrombosis service, track medication intake, and manage appointments. Replaced the previous Portavita system.

Quantifiable outcome

• Approximately 18,000 patients served (2022), making TZD one of the larger thrombotic services in the Netherlands
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core, major and minor.

• CAT (Centrum Antistolling Trombosezorg)coreStrategic or Co-development Partner · 1 March 2023TZD joined CAT on March 1, 2023, participating in the plug-and-play model for a future-proof national anticoagulation framework. TZD also partakes in the CAT Emergency Consultation Line serving approximately 100,000 VKA patients across 6 Dutch provinces. CAT membership includes Star-shl, Atalmedial, Certe, Saltro, LabWest, and TD Leiden.
• Canisius Wilhelmina Ziekenhuis (CWZ)coreChannel Partner/ Reseller/ DistributorCWZ performs blood collection and analysis (KCL laboratory) for TZD patients. Part of the original founding structure of TromboseZorg Dichtbij. Serves regions including Nijmegen and Druten.
• Result LaboratoriumcoreChannel Partner/ Reseller/ DistributorResult Laboratorium performs blood collection and analysis (KCHL laboratory) for TZD patients. Part of the original founding structure of TromboseZorg Dichtbij. Serves regions including Drechtsteden and Hoekse Waard. Handles invoicing for TZD.
• DicoonmajorChannel Partner/ Reseller/ DistributorDicoon performs blood collection for TZD in CWZ region, Rijnstate region, and Gelderse Vallei (ZGv) region. Provides online blood collection location finder. Responsible for blood collection for Ede region patients post-March 2026 transfer.
• Ziekenhuis RijnstatemajorChannel Partner/ Reseller/ DistributorRijnstate Ziekenhuis performs blood collection for TZD patients. Collaboration agreement in place. TZD participates in the hospital's anticoagulation committee.
• Ziekenhuis Gelderse ValleimajorChannel Partner/ Reseller/ DistributorPartnership agreement for anticoagulation care coordination. Gelderse Vallei patients (Trombosedienst Gelderse Vallei) transferred to TZD management as of March 21, 2026.
• Albert Schweitzer ZiekenhuisminorStrategic or Co-development PartnerCollaboration agreement in place. TZD participates in the hospital's anticoagulation committee.
• Beatrix Ziekenhuis (Rivas)minorStrategic or Co-development PartnerCollaboration agreement in place. Self-management training location at Beatrix Ziekenhuis, Gorinchem. TZD participates in the hospital's anticoagulation committee.
• Maasziekenhuis PanteinminorStrategic or Co-development PartnerCollaboration agreement in place for anticoagulation care coordination in Boxmeer region.
• RadboudumcminorStrategic or Co-development PartnerCollaboration agreement in place. Medical director participates in the NOAC/TAR platform, chaired by Radboud UMC.
• Landelijke Transmurale Afspraak (LTA) AntistollingszorgminorStrategic or Co-development PartnerTZD follows the LTA guidelines for information and switching between VKA and DOAC medications. LTA platform provides essential information for healthcare providers on anticoagulation transitions.
• Landelijke Standaard Ketenzorg Antistolling (LSKA)minorStrategic or Co-development PartnerTZD operates in accordance with the LSKA national standard for anticoagulation care chain coordination between first and second line healthcare providers.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/trombosezorg-dichtbij

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TromboseZorg Dichtbij